Table 3.
n=223 440 | Women without epilepsy | WWE with lamotrigine | WWE with carbamazepine | WWE with levetiracetam | WWE with valproate | ||||||||
n=221 662 | n=280 | n=94 | n=71 | n=51 | |||||||||
N (%) | N (%) | aOR (95% CI) | P values | N (%) | aOR (95% CI) | P values | N (%) | aOR (95% CI) | P values | N (%) | aOR (95% CI) | P values | |
Any hypertensive disorder | 16 542 (7.5) | 25 (8.9) | 1.20 (0.76 to 1.88) | 0.434 | 7 (7.4) | 0.97 (0.42 to 2.25) | 0.946 | 7 (9.9) | 1.32 (0.57 to 3.05) | 0.523 | 9 (17.6) | 2.93 (1.35 to 6.38)* | |
Gestational hypertension | 5381 (2.4) | 7 (2.5) | 1.07 (0.48 to 2.42) | 0.865 | 1 (1.1) | 0.48 (0.07 to 3.44) | 0.462 | 2 (2.8) | 1.32 (0.32 to 5.41) | 0.698 | 3 (5.9) | 3.31(1.02 to 10.77)† | 0.047 |
Mild pre-eclampsia | 6445 (2.9) | 11 (3.8) | 1.41 (0.75 to 2.66) | 0.291 | 2 (2.1) | 0.85 (0.21 to 3.49) | 0.824 | 3 (4.2) | 1.66 (0.52 to 5.30) | 0.39 | 5 (9.8) | 3.32 (1.18 to 9.35)* | 0.023 |
Severe pre-eclampsia | 4330 (1.9) | 6 (2.1) | 1.21 (0.50 to 2.53) | 0.783 | 4 (4.3) | 2.23 (0.81 to 6.12) | 0.120 | 3 (4.2) | 2.36 (0.74 to 7.50) | 0.146 | 1 (2.0) | 1.01 (0.14 to 7.37) | 0.991 |
Early onset pre-eclampsia | 1299 (0.6) | 3 (1.1) | 1.45 (0.36 to 5.87) | 0.602 | 2 (2.1) | 4.04 (0.98 to 16.76) | 0.054 | 2 (2.8) | 6.00 (1.47 to 24.59)* | 0.013 | – | – | – |
HELLP | 518 (0.2) | – | – | – | 2 (2.1) | 5.02(0.69 to 36.36) | 0.11 | – | – | – | 1 (2.0) | 8.54 (1.18 to 61.92) | 0.113 |
Eclampsia | 191 (0.1) | – | – | – | 1 (1.1) | 12.47 (1.73 to 89.91) | 0.078 | – | – | – | – | – | – |
Adjusted OR for maternal age, educational level, multifetal pregnancy, pre-existing diseases, folic acid supplementation.
*Not significant in sensitivity analyses when including BMI >30 kg/m2.
†Not significant in sensitivity analyses when including smoking or BMI >30 kg/m2.
AED, antiepileptic drug; aOR, adjusted OR; BMI, body mass index; HELLP, haemolysis, elevated liver enzymes, low platelets; WWE, women with epilepsy.